ClinicalTrials.gg
TerminatedNCT01370694Updated Mar 15, 2019Results posted

Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001)

A Phase 1 interventional study of MK-8808 and cyclophosphamide in Follicular Lymphoma, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-15.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Why this study was terminated
The study was terminated for business reasons.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 194 studies testing rituximab in Lymphoma, Follicular — 12 open to participants now, 24 under way, 6 of them phase 3. Rituximab · Lymphoma, Follicular.

Enrollment
166th of 188
7 · median 48
Started
2011
with 8 others
Phase 1
27 of 194
1 open now
Registered
132nd of 194
by date

Among the 194 studies testing rituximab in Lymphoma, Follicular, this one is the 166th largest by enrollment of the 188 interventional ones that give a count, is one of 9 that started in 2011, is one of 27 in phase 1, and was the 132nd registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

12 of the 194 studies testing rituximab in Lymphoma, Follicular are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies testing rituximab in Lymphoma, Follicular, or all of them as a file.
02

Study summary

This study will evaluate the safety, pharmacokinetics, and anti-tumor activity of MK-8808 in combination with cyclophosphamide, vincristine, and prednisolone (CVP), and as a single agent, for participants with B-lymphocyte antigen cluster of differentiation 20 (CD20)-positive follicular lymphoma who have had no prior chemotherapy. The primary study hypothesis is that MK-8808 will be safe and well tolerated in combination with CVP and as a single agent.

Read the detailed description

The study was terminated early by the Sponsor due to business reasons. All participants were discontinued from MK-8808 + CVP, but could continue to receive maintenance therapy with MabThera™ (rituximab) per standard of care.

03

Conditions studied

  • Follicular Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological diagnosis of CD20-positive follicular lymphoma, Grade 1, 2, or 3a (World Health Organization [WHO] 2008 classification) based on an excisional or incisional lymph node or a bone marrow biopsy.
  • Ann Arbor Stage III or IV disease.
  • (ECOG) performance status of ≤2.
  • >3 months with no expected need of immediate intervention to treat life-threatening complications.
  • Adequate organ function.
  • Participants must agree to use an adequate method of starting with the first dose of study drug through 12 months (for females) or 90 days (for males) after the last dose of study drug.

Exclusion criteria

Exclusion criteria:

  • Histological Grade 3b or with >50% diffuse architectural pattern.
  • Circulating malignant cells >25,000/mm\^3
  • Presence or history of central nervous system (CNS) disease (either CNS lymphoma or lymphomatous meningitis).
  • Prior treatment with chemotherapy, rituximab, any other anti-CD20 compound, or any other type of anti-cancer compounds.
  • Radiotherapy within 2 months prior to Cycle 1 Day 1.
  • Current participation or has participated in a study with an compound within 30 days prior to Cycle 1 Day 1.
  • Concomitant disease that requires continuous therapy with prednisone at doses >20 mg per day.
  • Any medical for prednisolone as being dosed in the CVP regimen.
  • Poorly controlled diabetes mellitus, as defined by institutional or local standards.
  • Grade >2 peripheral neuropathy.
  • Has one of the following:

    1. is (HIV)-positive
    2. is surface antigen positive (HBsAg+) or is positive for antibodies to Hepatitis B core antigen (anti-HBcAg+)
    3. has antibodies to virus
  • Has one or more of the following:

    1. Active tuberculosis based on institutional diagnostic criteria and local practice guidelines.
    2. Evidence of a tuberculosis infection based on a chest X-ray (CXR) or computed tomography (CT) scan performed within 3 months of dosing.
    3. History of a tuberculosis infection.
  • Major surgical procedure within 4 weeks prior to Cycle 1 Day 1.
  • Regular use (including "recreational" use) of any illicit drugs or recent history (within the last year) of drug or alcohol abuse or dependence.
  • Pregnant or breastfeeding.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    MK-8808 Combination Therapy

    Participants received MK-8808 375 mg/m\^2 intravenously (IV) + cyclophosphamide 750 mg/m\^2 IV + vincristine 1.4 mg/m\^2 IV (maximum dose of 2 mg IV) on Day 1 each cycle, plus prednisolone 40 mg/m\^2, orally on Days 1 to 5 of each cycle for a maximum of 8 cycles. Participants receiving clinical benefit could remain on MK-8808 375 mg/m\^2 IV starting 8 weeks after last dose of combination therapy, every 2 months for up to 2 years.

    Drug: MK-8808 · Drug: cyclophosphamide · Drug: vincristine · Drug: prednisolone

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Clinical and Laboratory Adverse Events (AEs) During MK-8808/CVP Combination Therapy

    An adverse event is any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment.

    Time frame: From first dose of combination therapy up to 24 weeks

  2. Number of Participants Experiencing Clinical and Laboratory AEs During MK-8808 Maintenance Therapy

    An adverse event is any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment.

    Time frame: From first dose of single agent MK-8808 up to 2 years

Secondary outcomes

  1. Maximum Concentration (Cmax) of Plasma Levels of MK-8808 When Used in Combination With CVP

    Cmax is a measure of the maximum concentration of the drug in the plasma as measured using plasma samples taken over specified time points.

    Time frame: Pre-dose and end of infusion in each 21-day cycle and at end of therapy visit (up to 24 weeks)

  2. Cmax of Plasma Levels of MK-8808 During Single Agent Maintenance Therapy

    Cmax is a measure of the maximum amount of drug in the plasma over time using samples taken at specified time points.

    Time frame: Predose and end of infusion in every other cycle and at end of therapy visit (up to 2 years)

  3. Lowest Concentration (Ctrough) of Plasma Levels of MK-8808 When Used in Combination With CVP

    Ctrough is a measure of the lowest level of drug in the plasma over time, using plasma samples collected at specified time points.

    Time frame: Pre-dose and end of infusion in each 21-day cycle and at end of therapy visit (up to 24 weeks)

  4. Ctrough of Plasma Levels of MK-8808 When Used as Single Agent Maintenance

    Ctrough is a measure of the lowest level of drug in the plasma over time, using plasma samples collected at specified time points.

    Time frame: Predose and end of infusion in every other cycle and at end of therapy visit (up to 2 years)

  5. Clinical Response of Tumor to MK-8808/CVP Combination Therapy

    The response of the tumor to MK-8808/CVP combination therapy was radiographically assessed using Response Criteria Evaluation in Solid Tumors (RECIST). Response categories of partial response (PR), complete resonse (CR), and uncomfirmed (CRu) central review.

    Time frame: Up to 2 years

07

Results

Posted Nov 25, 2015
Limitations and caveats
The study was terminated for business reasons. Not all planned analyses were performed

Participant flow

The study was terminated early by the Sponsor due to business reasons. All participants were discontinued from MK-8808 on 18 March 2014, but could continue to receive maintenance therapy with rituximab per standard of care.

Participant flow — Overall Study
MilestoneMK-8808 Combination Therapy
Started7
Completed1
Not completed6
Withdrew: Switched to rituximab4
Withdrew: Progressive disease2

Outcome measures

PrimaryNumber of Participants Experiencing Clinical and Laboratory Adverse Events (AEs) During MK-8808/CVP Combination Therapy

An adverse event is any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment.

Time frame:
From first dose of combination therapy up to 24 weeks
Reported as:
Number · Participants
Number of Participants Experiencing Clinical and Laboratory Adverse Events (AEs) During MK-8808/CVP Combination Therapy
ParticipantsMK-8808 Combination Therapy
Number of Participants Experiencing Clinical and Laboratory Adverse Events (AEs) During MK-8808/CVP Combination Therapy6
PrimaryNumber of Participants Experiencing Clinical and Laboratory AEs During MK-8808 Maintenance Therapy

An adverse event is any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment.

Time frame:
From first dose of single agent MK-8808 up to 2 years

No measurements were reported for this outcome.

SecondaryMaximum Concentration (Cmax) of Plasma Levels of MK-8808 When Used in Combination With CVP

Cmax is a measure of the maximum concentration of the drug in the plasma as measured using plasma samples taken over specified time points.

Time frame:
Pre-dose and end of infusion in each 21-day cycle and at end of therapy visit (up to 24 weeks)

No measurements were reported for this outcome.

SecondaryCmax of Plasma Levels of MK-8808 During Single Agent Maintenance Therapy

Cmax is a measure of the maximum amount of drug in the plasma over time using samples taken at specified time points.

Time frame:
Predose and end of infusion in every other cycle and at end of therapy visit (up to 2 years)

No measurements were reported for this outcome.

SecondaryLowest Concentration (Ctrough) of Plasma Levels of MK-8808 When Used in Combination With CVP

Ctrough is a measure of the lowest level of drug in the plasma over time, using plasma samples collected at specified time points.

Time frame:
Pre-dose and end of infusion in each 21-day cycle and at end of therapy visit (up to 24 weeks)

No measurements were reported for this outcome.

SecondaryCtrough of Plasma Levels of MK-8808 When Used as Single Agent Maintenance

Ctrough is a measure of the lowest level of drug in the plasma over time, using plasma samples collected at specified time points.

Time frame:
Predose and end of infusion in every other cycle and at end of therapy visit (up to 2 years)

No measurements were reported for this outcome.

SecondaryClinical Response of Tumor to MK-8808/CVP Combination Therapy

The response of the tumor to MK-8808/CVP combination therapy was radiographically assessed using Response Criteria Evaluation in Solid Tumors (RECIST). Response categories of partial response (PR), complete resonse (CR), and uncomfirmed (CRu) central review.

Time frame:
Up to 2 years
Reported as:
Number · Participants
Clinical Response of Tumor to MK-8808/CVP Combination Therapy
ParticipantsMK-8808 Combination Therapy
PR6
CR0
CRu0

Adverse events

Collected over Up to 30 days after last dose of CVP therapy (up to 28 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MK-8808 Combination Therapy—1/7 (14.3%)6/7 (85.7%)
Most frequent serious events
Most frequent serious events
EventMK-8808 Combination Therapy
Femoral neck fractureInjury, poisoning and procedural complications1/7
Most frequent other events
Showing 10 of 13
Most frequent other events
EventMK-8808 Combination Therapy
AnaemiaBlood and lymphatic system disorders1/7
TachycardiaCardiac disorders1/7
BlepharitisEye disorders1/7
HypersensitivityImmune system disorders1/7
BronchitisInfections and infestations1/7
GastroenteritisInfections and infestations1/7
PharyngotonsillitisInfections and infestations1/7
Skin infectionInfections and infestations1/7
Upper respiratory tract infectionInfections and infestations1/7
Alanine aminotransferase increasedInvestigations1/7

Baseline characteristics

Age, Continuous
Age, Continuous(Years)MK-8808 Combination Therapy
Mean56.1 ± 16.4
Sex: Female, Male
Sex: Female, Male(Participants)MK-8808 Combination Therapy
Female2
Male5
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2011 to primary completion in Dec 2014, 39 months.

Results were first posted in Nov 2015, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2011
First posted
Jun 10, 2011
StartActual
Aug 19, 2011
Primary completionActual
Dec 1, 2014
CompletionActual
Dec 1, 2014
Results first posted
Nov 25, 2015
Last update
Mar 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01370694
Responsible party
Sponsor
First posted
Jun 10, 2011
Start date
Aug 19, 2011
Primary completion
Dec 1, 2014
Completion
Dec 1, 2014
Results posted
Nov 25, 2015
Last update
Mar 15, 2019

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion